7-acylamido-3-hydroxy-3-cephem-4-carboxylic acid 3-sulfonates
13 claims: 6 independent, 7 dependent
- 13 ' ׳-Cephein-3-sulfonate ester compounds of the formula .:1. 1׳ I I: i ;, 1 וו III.‘. . '. .' • . ., יי׳‘.. , ,:׳ , .י . : '. 1 . ,׳;1 1 ׳ : 1 ׳ ׳. '. OH . !1< CoQ ’ .':. ;: ;i y‘‘ , ' i'l ;׳1.1.,:1: ' 1 ׳1', .’ !1 I i. . ...) 1;״F'i<״1i v ;. .׳ 1 :a!i: ::;0-Rj׳..' wherein. R׳ alkyl;haldalkyi;:י .' ! ,. ! .i;i,׳i1 1 ׳'i 0yT 1 1 ;ץ Ί.':ϊ 1:.f;.1: ׳גוי.,i: 1 !1 .‘.i 1 ':'! 1 cyanoalkyl, phenyl, 4-amino-4-cafboxybutyl, or R l. b 1' ;::.׳1.:׳i I }.A׳!. ;I.«! ;> .־־l> : I.’. : . ;. I : '! . l.!: 1 ,;';יי I . ״I 1-.ilי , .׳ ׳ .׳ , 1 ;׳ ';׳ . . I.': >' 1 1 i' ,.: is ¢. group, of ,the .fo^nul^ _ Λ ,., ,.,,. ,״ . : '. ״. ״ 1', I . , , , . ., ״ .: I .:.1 1 j .. . I ' ;נ ), :I , , ! II '. ^wherein a and a’ independently are hydrogen, Cj-C lower alkyl, Cj^ lower alkoxy, halogen;hydroxy, or nitro, Z is 0 or S;and . m is 0 or 1;or is a group of the formula P-CH f /י. .׳1/ ׳ ׳.׳ .. Q י ., ,:,. .. .. i;,,... wherein P is 2-thienyl, .3-thienyl,, phenyl or a substituted phenyl group of the formula wherein a and a. are as defined above, '.1, : < ׳ ' ! ׳' !׳׳ 1 .׳ .׳ ׳.,' .' ’ ' ' ־ ’ .' Q is hydroxyl, formyloxy, acetoxy, amino or pro- .: ,: :j ' : 1 : ,. ' . .: '1,, . .י ,. . ' י י. tected amino ׳ (as .' hereinbefore defined);: ! . ! or R is a group bf the formula ־ Ί ׳ ! : ! !: ׳.! r׳-ch 2 - ׳ ־.־ :. / . ־' ' • ' 1 > . t \ I I ‘ . . j ' , ! ._ I ' ;’ . . 1 ' ' . wherein R‘ is, 2-thienyl, 3-thiehyl;< . ' > ’ - - ' .י . * k .. . ׳.I . . Rj is Cj-Cg alkyl, phenyl,halophenyl, lower alkylphenyl, or nitrophenyl;־׳ ! . Rj is;hydrogen, bonzyl, 4-methoxybenzyl,4 ־-nitrobenzyl, . diphenylmethyl, 2,2,2-trichlorpethyl or t-butyl;and when is hydrogen the pharmaceutically acceptable non-toxic salts thereof.
- 1012. A process for preparing 3-cephem-3-sulfonate ester compounds of the formula wherein R, and R 2 areas defined in reacting a 3-hydroxy-3-cephem compound claim 1, which comprises of the formula I R1 wherein R is as defined-in. claim 1 and R^ is a carboxylic acid protecting ester forming group, with a sulfonyl halide of the formula 20 0 II R2-S-X II 0 wherein R 2 is as defined in claim 1 and X is a halogen;and if desired removing the carboxylic acid protecting ester forming group to provide the corresponding acid.
- 1214. A process for preparing compounds of the wherein R, and R 2 are as defined in claim 12, substantially as hereinbefore described with particular reference to Examples 4-9.
Independent claims9
281 paragraphs in 9 sections, as filed
. The.present invention relates to 7-acylamido-3- ץ alkylsulfonyloxy (and phenyl or substituted phenylsulfonyloxy)' ׳ i ' . I . . :
3-cephem-4-carboxylic acids and esters thereof, and to a process׳ for preparing said compounds which comprises the sulfonation of 3-hydroxy-3-cephem esters. The 3-cephem-3sulfonate esters are useful antibacterial compounds.
<sub>(</sub> . I , <'< '. 'י ־ u . > '* ;׳
׳. ; ׳-Acylan1ido-3-hydroxy-3-cephem-4-carboxyllc acid
Ϊ 1 ־ . j ; . ״ ׳ <sup>! 1</sup> '׳ <sup>1</sup> ; . ׳ ׳יו : י' י י y ., ׳<sup>!</sup>.' , esters are, reacted in an aprotic .solvent with alkyl<sup>!</sup> sulfonyl halides Or phenyl'and substituted :phenylsulfonyl j . <sup>1</sup> ' j ‘ <sup>1</sup> ' ־ I L t ‘ I 1 i ' י ' ' ‘ I ־ . .' halides ׳ hi i /<sup>1</sup> '׳ / y <sup>:</sup><sup>1</sup>' י' י י 'י י'. '/J. ׳ ' ' יי<sup>t0</sup>7' provide thecorresponding3-alkylsulfonyloxy-or phenyland \ ...י' ' v : ' ' .' *' ;i ' ( 7 ,., ' ., 7 ' 7 ' .
substituted phenylsulfonyloxyL3-cephem-4-carbbxylic acid . 7W. .',.7 ,י'.'.. ׳TW. ., י -י' ‘ י ’ <sup>:</sup> י י י ' '' esters. The C. .ester,group.ds removed to provide the ,.
' ’ ' ' ' יי ϊ' '' 7 ־ ,'I Ϊ : י. .'.־ יי' יי'' ''־. < י ׳ ' י-acylMido-3(C^-C<sub>6</sub>)aikylsulfonyloxy- , (or phenyl! ,and substituted phenylsqlfqnylpxy) 3Tcephemr,4-carbo,xylic add antibiotic
׳. < : .: , i j . י י י’ ׳ ' ־. ,׳ compound, :
; , , 'j <sub>1;</sub>y ,.,, - ,!.<sup>,</sup>י '*־׳׳ י.'<sup>,,</sup>‘ ״-<sup>1</sup> י י' י ׳ '׳ ״ י י; 1 ז <sup>;</sup>׳;, :,׳,ו ׳ ? י > The cephalosporin 5-sulfonate,esters of this ,: invention are represented by the following; general formula I.
'“i <sup>1</sup> 11 7 :־ ’ו ,' J , ; ,,, , !/Λ.’
H : . v ''
<img file="IL44360A_D0001.tif" />
wherein R is C^-Cg alkyl, Cj-Cj haloalkyl, Cj-Cj cyanoalkyl., phenyl, .4-amino-4־carboxybutyl, ,. <sub>s</sub> : 2 - ־ 44360/2 or R is a group of the formula wherein a and a* independently are hydrogen, <sup>,1</sup>.¾.:.
Cj-C^ lower alkyl, Cj-C^ lower alkoxy, halogen,
- _ ’u,t . ״*,׳h י r ' '' , י. י hydroxy, or nitro; <sup>1</sup>. ,;׳
Z<sup>;</sup>is 0 or S; and
,. , j־ I /* : :<sup>1</sup> . ׳ m is 0 or 1;
A <sup>1</sup> ' <sub>t</sub> 1 י ),. V 1- .־ λ 1,1 H ׳ יJ, /. . 1« י י or R is a group of the formula <sup>1</sup> ' (1 ’.1 יד ־ ״ .׳<sub>}</sub>‘ ‘ )
P-CH-׳. '..
whereinP is 2-thienyl, 3-thienyl, phenyl or a substituted phenyl group of the formula, ׳ I ί 44360/2
ז ׳ wherein a and a* ar© as defined above,
Q is hydroxyl, formyloxy, acetoxy, amino or protected amino (as hereinbefore defined); or R is a group of the formula
R’-CV
”<sup>1</sup>'.׳ .? .:..:י.:.. . , wherein R is 2-thienyl, 3-.thienyl; ,
R<sub>2</sub>HsC<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, halophenyl, lower alkylphenyl, or nitrophenyl; ;. <sup>1</sup> : ' .
Rj is hydrogen, benzyl, 4-methoxybenzyl,4-nitrobenzyl, diphenylmethyl, 2,2,2-trichloroethyl or t-butyl;
and when Rj is hydrogen the pharmaceutically acceptable . non-toxic salts thereof.
In the foregoing definition of the compounds provided by this invenition, the term Cj-Cg alkyl refers to the straight and branched chain alkyl hydrocarbon<sub>;</sub>groups such as, , methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, n-amyl, isoamyl, or n-hexyl; Cj-Cj cyanoalkyl refers to such groups as cyahomethyl, 2-cyanoethyl, 3-cyanopropyl, or, ,<sup>י</sup> .,,ו . . i . ‘ . . *’ ’ ׳ ־
2-cy0nop.1<sup>,</sup>opyl; C<sub>1</sub>-C<sub>4</sub> lower alkyl refers to the straight and branched chain lower alkyl hydrocarbon groups‘such as methyl,' ethyl, n-propyl, isopropyl, n-butyl, or t-butyl; lower alkoxy refers to methoxy, ethoxy, isopropoxy, or n-butoxy. As used herein, the term halogen refers to fluoro, chloro, bromo, and iodo.
מ,׳ ; ; י
Illustrative of the groups in the above definition represented by the following formula where m is 0 are !!J < יי :/./ ? ., <sub>V</sub> RO
V ®Λ־־.
... u->c=y.τ phenylacetyl, 4-methylphenylacetyl, 3-ethylphenyiacetyl,
4-isopropylphenylacetyl, Z-methylphenylaeetyl, 4-chiprophenyl? .־ יי’.‘ ’יי. י י י . , * <sup>1</sup> י<sup>,</sup> י' y acetyl, 4-nitrophenylacetyl, 4-,bromophenylacetyl, 2,4-dlchlorophenylacetyl, 3-bromophenylacety1, 4-iodophenylacetyl,
2- fluorophenylacetyl, 3,4-dihydroxyphenylacetyl, 4-hydroxy- ' <sup>1</sup> י י . ‘ <sup>1</sup> . ' , <sup>1</sup> ., ׳. . .. j , ! . ' i <sup>ז</sup> , ’ <sup>-</sup> ‘ , ' phenylacetyl, 3-hydroxyphenylacetyl, 2,6-dlmethpxyphenylacetyl,
3- carboxyphenylacetyl3-ethoxyphenylacetyl, 4־methoxyphenylacetyl,
3,-4-din1ethoxyphenylacetyl, 4-t-butoxyphenylacetyl, or 3-nitrophenylן י . 1 , ׳ . . ’׳ ί . ז י .f , acetyl. When in the above formula m 0 1 and Z represents -0-, ,, <sup>!</sup> 1' '; ,‘ 1’ ♦ 1 . ) ׳ * ’ j! ! i u ( ‘ t- ' i 1 ׳ 1 י י ’ <sup>1</sup>־. ί׳;.* ־ ף;׳; ,׳.' illustrative groups are the following: Phenoxyacetyl, 4-hydroXyphenbxy<sup>;</sup> י. <sub>)</sub> . ! -! ׳ .:?./ ,. y. iy . <sup>;</sup> י י י.
acetyl, 3-hydroxyphenoxyacetyl, 4-chlorophenoxyacetyl, 3-bromophenoxy1 י י :.'*. 'י'<sup>,</sup> יי.‘ י י ׳ י i > . .: I ,ן .; ן; ,׳ > , י י י ! י' י..
• acetyl, 3-ethylphenoxyacetyl, 4-methylphenoxyacetyl,3-hydroxy'י' ‘ ׳ i >׳ י ’.'.״: “T : :'<.־i ί ’ . ' ; . , ׳ . .. ; ' >,.!'
3-methy!phenoxyacetyl, 3-nitrophenoxyacetyl, 2-chlorophenoxyacetyl, 4-t<sup>: 1</sup> .*/ ΐ <sup>1</sup> . ׳ . ' . <sup>1</sup>יי י'>' Ί .׳. ' .י 1 י . ’ ; i :. :1. . , ׳<; .׳ ׳, : .’ -, ' butylphenoxyacetyl, 4-methoxyphenoxyacetyl, 3,4-dimethoxy- . , ,.
phenoxyacetyl, 4-isopropoxyphenoxyacetyi, or 4-nitrophenoxyacetyl.
When in the foregoing formula m e 1 and Z represents -S-, illustrative gjoups ׳ I . .i' 1 : י'ר :: f ׳: . : ״' - ' ('!' <sub>:</sub> .;.I ר ., ן.,' .,.-J , are the following: Phenylmercaptoacetyl, 4-chlorophenylmercaptoacetyl,
L-׳ <sup>;</sup> . .- ’ ., ' '.J ' ' ί , - , ’1 Γ-. ׳ “ <sup>,</sup>‘,:;:y' 1 ׳/ :,,.
3-hydroxyphenylmercaptoacetyl, 3,4-dimethylphenylmercaptoacetyl, 3,4-dich' f <sup>;</sup> ׳ ' y : , 1 . . y . . ; ;:־.,׳:,,ί , lorophenyImercaptoacety1, 3-bromophenylmercaptoacetyl, 4-fluorophenylmer* 1 ' < L ' I > י . ‘ f t I , '1 I ί . I f <sup>1</sup> . l ' ' ; * ' f I I ' ' captoacetyl,2,6-difluorophenylmercaptoacetyl, 4-nitrophenylmercaptoacetyl, , V y ־ . . x ’ '' ' . ' or 3-fluorophenylmercaptoacetyl.
When in formula
I R represents a group of the formula
P - CH illustrative acyl groups,
R-C»0, are the mandeloyl group of the formula
<img file="IL44360A_D0002.tif" />
the 0-formyl derivative thereof represented by the following formula
<img file="IL44360A_D0003.tif" />
the phenylglycyl group represented by the formula
<img file="IL44360A_D0004.tif" />
as well as those 2-thlenyi and 3-thienyl acyl ' ' ‘ ' '* <sup>1</sup> י' ' יי<sup> ;</sup> *’< ’ I A 1 ״. . . .
groups׳ wherein ׳the above formula the phenyl group is replaced with a 2-thienyl or 3-thienyl ring.
Illustrative of the foregoing acyl groups are 4-methyhnandeloyl, 4-hydroxymandeloyl,
3-hydroxymandeloyl, 3-bromomandeloyl, 4-chloro' <sup>1</sup> .י */ . 1 1 .1.' * <sup>1 1</sup> '/ ' . <sup>1</sup> ' ׳ j .*.*' mandeloyl/ .3-methyl-4-fluoromandeloyl, 2-fluoromandeloyl, 4-fluoromandeloyl, 4-methoxymandeloylJ
3,4-dimethyl-Orformylmandeloyl, 4-chloro-0-formylmandeloyl, 3-amino-O-fprmylmandelbyl, 3-bromo-0formylmandeloyl, 3,4-dimethoxy-0-formylmandeloyl, 0-acetyl- 7 44360/.2 ׳ ’ י . . ‘ י<sup>:</sup> i י mandeloyl, 0-acetyl-4-hydroxymandeloyl, o^-formyloxy-
2- thienylacetyl, phenylglycyl, 4-hydroxyphenylglycyl,
[ i t י י י.<sup>,</sup>.!׳ ,׳.<sup>;!</sup>י י<sup>,</sup> נ * .,./ /׳ ׳׳ . i<sup>:</sup>יי !/׳
3- chlorophenylglycyl, 3-hydroxyphenylglycyl, 4-methoxy- !
phenylglycyl,o(-a1nino-2-thionyla;Qtyl<sub>)</sub>
When in the foregoing formula ,R represents a group of the formula R'-CH^-, illustrative of the acyl groups of the formula I are the following: 2-thienyl.״ ׳ .׳: j .1<sup>1</sup> : . ׳.׳,.׳. ..«., 1 >״' . : .י.«י!. ו c ׳<.: יד. 1 ׳! j acetyl, 3ךthienylacetyl, <sup>1</sup> : ! :
ין, י' ׳ I ; i l. I'.'i: 1 * .!. 1׳ V : u;׳ T . ::!-I[
The sulfonate esters of this invention are ; .: ׳ . >: . !. ί.I a 3';.?*: J . , '1 ' <sup>1</sup> 11'.', prepared by reacting a 7-acylamido-3-hydroxy3־-cephem-
4- carboxylic acid ester with a C<sub>1</sub>-C<sub>fi</sub> alkylsulfonylhalide, a phenylsuifohyl haiide; or a substituted<sup>1</sup>’phenylsulfonyl halide at a temperature between about -5 and 35°C. in an
I <sup>1</sup>י ; / <sup>1 ;</sup> ׳ I ; ; . .f u ' ; ;1 , ׳' . י' 1 ’ <sup>1</sup> > ן ' ־ ׳ *, .I I '1 ‘ J ’ <sup>1</sup> ' j aprotic solvent in the presence of a hydrogen halide ac<sup>1</sup> . .' . ; i . <sub>;</sub> . ' | ־ I 1[ 1 . ., > ׳ . / j .'61)11)1.<sup>,1</sup> \ . ו י-captor. 7-Acylamido-3־hydroxy-3-cephom-4-carboxylic acid : ! V 6 1<sup>,</sup>1 '־1 .׳ I <sup>1</sup>'ί.׳״: /';.!,.λ‘. I ׳ - ' ‘.'.I ’ / f .'(I .<sup>,</sup>I !.
esters which can be used in the preparation are represented by the following formula II
Hj 1 ' I | ., 1 ' ' <sup>,4</sup> ' ; , ' 1. . ' ’ ’ 1. ’ L I
Ο H
<img file="IL44360A_D0005.tif" />
COORj wherein R has the same meaning as defined for formula I and Bj is a carboxylic acid protecting ester forming group.
Representative of the alkyl and phenylsulfonyl halides which can be used are methanesulfonyl chloride, methanesulfonyl bromide, ethanesulfonyl chloride, n-butanesulfonyl chloride, n-hexanesulfonyl bromide, phenylsulfonyl chloride, p-chlorosulfonyl chloride, p-fluorosulfonyl chloride, p-toluenesulfonyl chloride, p-toluenesulfonyl bromide, 5- or A-nitrobenzenesulfonyl chloride or bromide, 3-ethylbenzene-10 sulfonyl chloride or 5-bromobenzenesulfonyl chloride or .׳.bromide.
Aprotic solvents which can be employed are the ether solvents such as tetrahydrofuran, dioxane or the dimethyl ether of ethylene glycol. A preferred solvent which can be used is dimethylacetamide.
The reaction is carried out in the presence of a hydrogen halide acceptor such as an unreactive tertiary amine such as triethylamine or pyridine or an alkylene oxide, for example, propylene or butylene oxide. The preferred hydrogen 20 halide acceptor is propylene oxide. The tertiary amine type acceptors tend to cause isomerization of the 5-cephem to a 2-cephem compound. With an alkylene oxide such isomerization is kept to a minimum with most sulfonyl halides.
The reaction is carried out by the addition of the . stoichiometric amount of the sulfonyl halide, or a slight excess thereof, to a solution of the 5-hydroxy-5-cephem ester In the aprotic solvent, containing at least a stoichiometric amount of the: hydrogen halide acceptor. The reaction mixture is stirred at a temperature preferably between 10 and 25״C.
for between 5 and 12 hours. The sulfonate ester product is
X-4205 ־9־ recovered from the reaction mixture by extraction with an organic solvent such as ethyl acetate or methylene chloride and is recovered from the extract. The 3-sulfonate esters can be purified by chromatography over silica gel.
When the starting material contains a functional group in the 7-acylamido side chain which is capable of reacting with the sulfonyl halide, the reactive group is protected with a suitable protecting group. For example, the a-amino group of the phenylglycyl side chain can be protected 10 during the sulfonyl ester formation with a variety of amino protecting groups. For example, the urethan protecting groups such as t-butyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, benzyloxycarbonyl, or p-nitrobenzyloxycarbonyl; the enamine protecting groups formed with ethyl acetoacetate, or acetyl acetone; the trityl group and other amino protecting groups. An amino substituent of a phenyl group in the 7-side chain can also be protected with the same groups. Likewise, an hydroxy group located in the 7-acylamido side chain, for example, in the marideloyl side chain, is protected with a 20 readily removable group such as, for example, the formyl group and the trichloroethoxycarbonyl group. Following the sulfonylation reaction such protecting groups are removed. Also, the C<sub>4</sub> carboxylic acid protecting group is removed to provide 3-sulfonyloxy-3-cephem-4-carboxylic acid antibiotic compound.
The foregoing description of the preparation of the sulfonate esters is illustrated in the following reaction scheme.
X-4205
<img file="IL44360A_D0006.tif" />
<img file="IL44360A_D0007.tif" />
ester removal
<img file="IL44360A_D0008.tif" />
wherein R, R!, and R<sub>s</sub> have the same meanings as previously defined«
In one embodiment of the invention, p-nitrobenzyl (N-t-butyloxycarbonyl-D-phenylglycylamido)-5-hydroxy-5 cephem-h--carboxylate is reacted with methanesulfonyl chloride in dimethylacetamide in the presence of propylene oxide at about 5“C. to yield 7-(N-t-butyloxycarbonyl D-phenylglycylamido)-5-methylsulfonyloxy-5-cephem-^-carboxylic acid p-nitrobenzyl ester. The product is hydrogenated over prereduced palladium on carbon catalyst in an inert solvent to effect removal of the p-nitrobenzyl ester group and the de50
X-U2O5 esterified product is then reacted with p-toluenesulfonic acid in acetonitrile to effect the removal of the t-butyloxycarbonyl group and provide the antibiotic 7-(D-phenylglycylamido )-J-methylsulfon yloxy-3-cephem-4-carboxylic acid. The starting materials employed in the preparation of the compounds of the present invention are prepared by reacting a 7-acylamido-5-exomethylenecepham-U-carboxylic acid ester or a 7-aminp-5-exomethylenecephan1-4-carboxylic acid ester with ozone in an inert solvent at a temperature between 10 -80 and 0’C. to form the ozonide derivative of the 5exomethylene double bond. The ozonide intermediate, which is not isolated, is decomposed by reacting the ozonide in situ with a mild reducing agent such as sodium bisulfite, or preferably, sulfur dioxide, to provide the corresponding
5-hydroxy-5-cephem-4-carboxylic acid ester.
The ozonolysis of a 7-amino-5-exomethylenecepham-Ucarboxylic acid ester or a 7-acylamido-5-exomethylenecepham-4 carboxylic acid ester of the following formula III is carried out by passing ozone through a solution of the 5-expmethylene 20 cepham ester in an inert solvent at a temperature between about -80 and 0״C. The exomethylene double bond reacts with ozone to form in situ an intermediate ozonide which is decomposed, as hereinafter described, to form the J-hydroxy5-cephem ester of the formula IV.
X-H203
־12־
<img file="IL44360A_D0009.tif" />
<img file="IL44360A_D0010.tif" />
IV
In the above formulae, R is hydrogen or an acyl group derived from a carboxylic acid and which acyl group is non-oxidizable under the described ozonolysis conditions. R! is an ester forming group and preferably one which is easily removed under hydrogenolysis, or acid or base hydrolysis conditions.
Ozone gas is prepared by means of an ozone generator of the type commonly used in synthetic and analytical chemical work to produce ozone by the action of an electric discharge on oxygen. One such ozone generator is that manufactured by the Welsback Corporation. The ozone is generated in a stream of oxygen'which is then passed directly into the ruction vessel. The percentage of ozone contained in the oxygen stream '.'.can be varied as desired, for example, by varying the rate of flow of. oxygen through the ozonizer as well as by varying the intensity of the electric discharge. The percentage of ozone in the oxygen stream can be determined iodometrically by
X-4205 ־15־ titrating with sodium thiosulfate the amount of iodine liberated from a standard solution of potassium iodide by ozone from, the generator. The percentage of ozone in the oxygen stream is not critical, however, for convenience in .carrying out the ozonolysis method of this invention, an estimate of the amount of ozone flowing into the .reaction . mixture enables one to determine the time at which the desired reaction should be complete and. thus minimizes the formation of over oxidation products.
Alternatively, the ozonolysis reaction can be followed chromatographically. For instance, a small aliquot of the reaction mixture is withdrawn, the ozonide decomposed, and the amount of unreacted starting material and 3-hydroxy3-cephem product present in the sample is assessed by a comparison of the thin layer chromatogram with that of a known amount of starting material and a 3-hydroxy-3־cephem compound.
Inert solvents which can be used in the ozonolysis are those solvents in which the 3-exomethylene cepham esters 20 are at least partially soluble and which are unreactive with ozone under the described conditions. Commonly used organic solvents such as methanol, ethanol, ethyl acetate, methyl acetate, and methylene chloride are satisfactory.
The concentration of the starting material in the inert solvent is not critical and it is preferred to use a solvent volume sufficientto form a complete solution.
The preferred temperature in the ozonolysis reaction is between about -80 and-50*C.
When ozonide formation is complete as determined by 30 either method described above, any excess ozone present in the
X-U203 ־*<sup>11</sup>־ reaction mixture is purged from the mixture by bubbling nitrogen or oxygen through the mixture.
Following the removal of any excess ozone, the ozonide is decomposed by adding to the reaction mixture a mild reducing reagent selected from the group consisting of sodium bisulfite, sulfur dioxide, and trimethyl phosphite to provide the J-hydroxy-J-cephem-L-carboxylic acid ester. The decomposition is carried out by adding an excess of the reducing reagent and then stirring the reaction mixture at a temperature of about -80 to 0״C. until the reaction mixture is negative in the potassium iodide-starch test.
A preferred reagent for decomposing the intermediate ozonide is gaseous sulfur dioxide. This reagent is preferred since it is completely volatilized from the reaction mixture during the subsequent work-up and thus does not complicate the recovery of the reaction product.
The 7-acylamido-3-hydroxy-3-cephem-L-carboxylic acid esters are recovered from the reaction mixture by first evaporating the mixture to dryness and thereafter extracting the 20 product from the residue, Alternatively, N-acylated 3-hydroxy3-cephem esters can be recovered from the organic liquid phase of the decomposition mixture by separating the liquid phase from insolubles, and after washing and drying, the organic layer is evaporated to yield the 5-hydroxy ester.
The 5-hydroxy nucleus ester, a 7-amino-5-hydroxy-5cephem-U-carboxylic acid ester, is best isolated in the form of a salt as, for example, the hydrochloride or hydrobromide salt.
When an ester of 7-amino-5-exomethylenecepham-k50 carboxylic acid (formula III, R־H) is ozonized, it is
X-U203 -15preferable to use a salt of this nucleus, for example, the hydrochloride or p-toluenesulfonate salt.
The starting materials for the preparation of the 5-exomethylenecepham eaters are prepared by reacting a
7-acylamido cephalosporanic acid with a sulfur containing nucleophile according to known procedures to effect the nucleophilic displacement of the acetoxy group of the cephalosporanic acid and provide a 7-acylamido-5-thiosubstitutedmethyl-5-cephem-k-carboxylic acid. The 5-thiosubstituted cephem product is then reduced with hydrogen, in the presence of Raney nickel or with zinc/formic acid in the presence of dimethylformamide to produce the 5-exomethylenecepham acid. For example, 7-phenylacetamidocephalosporanic acid is reacted with potassium ethyl xanthate to yield 7-phenylacetamido-5ethoxythionocarbonylthiomethyl-5-cephem-k-carboxylic acid which on reduction with zinc/formic acid in the presence of DMF yields 7-phenylacetamido-5-exomethylenecepham-U-carboxylic acid of the formula
<img file="IL44360A_D0011.tif" />
COOH
Likewise, the 5-exomethylenecepham nucleus of the formula
<img file="IL44360A_D0012.tif" />
X-4205 can be prepared by reacting a.7-acylamido-?-exomethylenecepham-4-carboxylic acid ester with phosphorus pentachloride (PCI5) in methylene chloride in the presence of pyridine to obtain the intermediate imino chloride. The imino chloride is reacted with methanol in the cold to afford the imino ether. The imino ether readily undergoes hydrolysis to provide the
7-amino-?-exomethylenecepham-4-carboxylic acid ester hydrochloride. The ester group is then removed to yield the 5exomethylenecepham nucleus.
An ester of the ?-exomethylenecepham nucleus can be acylated with the desired derivative of a carboxylic acid to provide the 7־acylamido-?-exomethylenecepham-4-carboxylic acid ester and the acylated ester ozonized to the ?-hydroxy ester starting material, of the formula II. Alternatively, an ester . of the?-hydroxy-7-amino-?-cephem nucleus can be acylated under non-anhydrous conditions to yield the 7-acylamido-?-hydroxy-?cephem-4-carboxylic acid ester. The acylation of these nucleus esters is carried out under the conditions employed for the acylation of 7-aminocephalosporanic acid. However, in the acylation of a 7-amino-?-hydroxy-?-cephem ester, the acylation is preferably carried out in an aqueous medium, for example, in aqueous acetone or aqueous acetonitrile.
The 7-acylamido-?-alkyl- or phenylsulfonyloxy-?cephem-4-carboxylic acid esters (formula I, R! ester) are useful as intermediates in the preparation of the free acid antibiotic forms of the compounds. Ester forming groups within the definition of R! are all known groups commonly employed to protect the C<sub>4</sub> carboxylic acid group of the cephalosporin molecule while reactions involving other groups in the moleeule are performed. These ester forming groups are readily
X-420? 17־removed to provide the free acid by known reduction or hydrolysis procedures. For example, the p-nitrobenzyl ester group is removed via catalytic hydrogenolysis over palladium on carbon; the diphenyltnethyl group (benzhydryl) is removed with trifluoroacetic acid in anisole at about 10°C.; the p-methoxybenzyl group is removed with trifluoroacetic acid at about 10°C. [j. Org. Chem., 56, 1259 (1971)]» the 2,2,2-trichloroethyl group is removed with zinc and acid [j. Am. Chem. Soc. 88, 81966) 2ל)] ; the b enzyl ester group is removed via catalytic hydrogenolysis over palladium catalyst [j. Org. Chem.,
27, 1581 (1962)]; and the tertbutyl group is removed as described in J. Org״ Chem., 51, (1966).
In the preparation of the 5-sulfonate esters of this invention a minor amount of the corresponding 2-cephem isomer is sometimes formed. The preparation of the tosylate esters is generally accompanied by more isomerization to the 2-cephem isomer than the preparation of the alkylsulfonate esters. When the amount of 2-cephem-5-sulfonate ester formed in the sulfonylation reaction is significant, the mixture of 2- and 20 5-cephem sulfonates can be separated by chromatography over silica gel. Preferably, however, the isomer mixture is oxidized with a peracid such as m-chloroperbenzoic acid or peracetic acid to form the sulfoxides thereof. As is known in the art the sulfoxide formation of a 2-cephem is accompanied by isomerization to the 5-cephem isomer [j. Am. Chem. Soc., 35 <sub>f</sub> 2U50 (1970)]. The 5-cephem5־-sulfonate ester sulfoxide is then reduced to the sulfide, for example, with a phosphorus halide such as phosphorus trichoride. Accordingly, any 2cephem isomeric product present in the desired 5-cephem-sulfonate ester can be converted to the desired 5-cephem isomer.
X-4205 -18The γ-acylamido-3-eephem-3-sulf0nate esters of the formula I wherein R! is hydrogen (the free acid form) are antibiotic substances which are useful in combating infections attributable to gram-postive and gram-negative bacteria and also penicillin resistant staphylococci. The antibacterial activity of these sulfonate esters is illustrated by the following in vitro test data obtained with representative compounds. In Table I below, the minimum inhibitory concentration (MIC) for representative compounds against gramnegative bacteria is presented. The data were obtained by the standard Gradient-Plate method.
X-U2O5
VI 0
טו ο
r TABLET
טו ο Antibiotic Activity of Cephalosporin Sulfonates vs, Gram-Negative Bacteria
OS
<td></td><td colspan="6"> Test Compound<sup>1</sup></td>
<td> Test Organism</td><td colspan="6"> Minimum Inhibitory Concentration (mcg./ml.)</td>
<td></td><td> 1</td><td> 2</td><td> 5</td><td></td><td> 5</td><td> 6</td>
<td> Shigella.sp.</td><td> ז.10</td><td> 7.0</td><td> 6.5</td><td> 19.5</td><td> .16.5</td><td> 15.6</td>
<td> Escherichia coli</td><td> 11.0</td><td> 15.1</td><td> 8.8</td><td> 16.5</td><td> 24</td><td> 19.5</td>
<td> Klebsiella pneumoniae</td><td> 6.5</td><td> 7.0</td><td> 5.5</td><td> 9.5</td><td> 16.5</td><td> 5.5</td>
<td> Aerobacter aerogenes</td><td> 5.5</td><td> 5.5</td><td> 6.0</td><td> 16.5</td><td> 12.0</td><td> 8.8</td>
<td> Salmonella heidelberg</td><td> 2.0</td><td></td><td> 6.0</td><td> 125</td><td> 15.5</td><td> 7.0</td>
<td> Pseudomonas aeruginosa</td><td> >200</td><td> >200</td><td> >200</td><td> >200</td><td> 200׳</td><td> 200׳</td>
<td> Serratia marcescens</td><td> no</td><td> 120</td><td> 180</td><td> 200׳</td><td> 200׳</td><td> 100</td>
טו ο
Γ
Μ
Ο kN
TABLE I (cont.)
Test compounds numbered 1-6 are as follows:
-- 7-[2-(2-thienyl)acetamido]-5-methylsulfonyloxy-5-cephem4-carboxylic acid.
-- 2)-2]-ץ-thienyl)acetamido] -5-ethylsulfonyloxy-5-cephem4-carboxylic acid.
. j^.(2-thienyl)acetamidol-5’D-butylsulfoDyloxy-5-eephem4-carboxylic acid.
2)-2].ץ אל-thienyl)acetamido]-5־(p-toluenesulfonyloxy)-5-cephen14-carboxylic acid.
טו carboxylic acid.
- 7-(D-phenylglycylamido)-5-methylsulfcnyloxy-5-cephen-Ucarboxylic acid.
In the same test method, the cephalosporin sulfonate esters inhibit the growth of clinical isolates of penicillin resistant Staphylococcus.
The 7-acylamido-5־cephem-5-sulfonate esters represented by the formula I when R! is hydrogen, form pharmaceutically acceptable salts with inorganic and organic bases. For example, the sodium, potassium, and calcium salts can be . prepared with sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium carbonate, or calcium hydroxide. Amine 10 salts are formed with amines such as benzylamine, 2-aminoethanol, diethanolamine, or diisopropylamine. Compounds of the formula I wherein R-C(0)- represents the phenylglycyl side chain form acid addition salts with suitable mineral and organic acids. For example, the hydrochloride, hydrobromide, and sulfate salts can be formed with hydrochloric, hydrobromic, and sulfuric acids. Likewise, the p-toluenesulfonate salt of the amine can be formed with p-toluenesulfonic acid. Such salts of the C4 carboxyl group and an amino group of the C<sub>7 </sub>side chain are useful in purifying the free acid form of the 20 antibiotic and in preparing acceptable pharmaceutical formulations for administration.
The compounds of the formula I wherein R! is an ester group are useful intermediates for preparing the free acid forms of the antibiotic.
Illustrative of the compounds of the invention represented by the formula I are 7-[2-(2-thienyl)acetamido]5-methyls.ulfonyloxy-5-cephem-4-carboxylic acid, [2-(2-furyl)acetamido) -3-ethylsulf0nyloxy-5 ־ cepbem-h-carboxylic acid,
X-U20J
-phenylacetamido-3 -(p-toluenesulfonyloxy)-3-cephem4-carboxylic acid,
7-(l|-chlo rophenylmercapto acet amido )-3-methyl8ulfonyloxy-3-cephem-U-carboxylic acid,
7-phenoxyacetamido-3-n-propylsulfonyloxy-3-cephem4-carboxylic acid,
7-cyano acetamido-3-methylsulfonyloxy-3-cephem-kcarboxylic acid,
7-(D-mandelamido )-3-methylsulfonyloxy-3-cephem-1!-.
carboxylic acid,
7־(D-phenylglycylamido)-3-methylsulfonyloxy-3-cephemU-carboxylic acid, ץ_(ϋ-4-hydroxyphenylglycylamido)-3-ethylsulfonyloxy-
3-cephem-4-carboxylic acid,
7-(0-formyl-D-mandelamido)-3-(p-toluenesulfonyloxy)3-cephem-U-carboxylic acid,
7-(tetrazol-l-acetamido)-3-methylsulfonyloxy-3cephem-4-carboxylic acid,
7-(5-amino-5-carboxyvaleramido )-3-(p-toluene20 sulfonyloxy)-3-cephem-L-carboxylic acid,
7-acetamido-3-benzenesulfonyloxy-3-cephem-4carboxylic acid,
7-(a-sulfophenylacetamido)-5-ethylsulfonyloxy-5cephem-U-carboxylic acid,
7-(a-carboxy-L-chlorophenylacetamido)-3-n-butylsulfonyloxy-3-cephem-3-carboxylic acid, and the pharmaceutically acceptable non-toxic salts thereof.
This invention is further illustrated by the following examples of the preparation of starting materials
X203 and compounds of the invention.
A. Preparation of Starting Materials Example 1 p-Nitrobenzyl 7-amino-3-methylenecepham-4-carboxylate hydrochloride.
To a solution of 965 mg. (2 mmole) of p-nitrobenzyl T-phenoxyaceta1nido-3-methylenecepham-4-carboxylate in 10 ml. of methylene chloride were added 175 mg. of dry pyridine and 460 mg. of phosphorus pentachloride and the mixture was stirred at room temperature for 6 hours. One ml. of isobutanol was added to the mixture which was then stored at 0°C. overnight. The reaction product, p-nitrobenzyl 7-amino-3methylenecepham-4-carboxylate hydrochloride, which formed as a crystalline precipitate was filtered to yield 4?0 mg. (58 per cent yield).
Elemental Analysis for C<sub>15</sub>H1<sub>e</sub>N30<sub>5</sub>S01 Theory: C, 46.69; H, 4.18; N, 10.89 Found: C, 46.40; H, 4.20; N, 10.62 I.R. (Nujol Mull)
2q Carbonyl absorption at 5.65 (β-lactam and
5.75 (ester) microns.
N.M.R. (DMSO d<sub>e</sub>) signals at 6.34 (2d,2H, C<sub>2</sub>-H<sub>2</sub>), 4.98 (d, IH, C<sub>e</sub>-H); 4.7-4.4 (m, 6h, C<sub>4</sub>-H, ester CH<sub>2״</sub> C<sub>4</sub>-CH<sub>2</sub> and C<sub>7</sub>-H); and 2.4-1.6 (m, 4h, aromatic H) tau.
Example 2 p-Nitrobenzyl 7-amino-3-hydroxy-J-cephem-4-carboxylate hydrochloride.
A solution of 4 g. of p-nitrobenzyl 7-amino-330 methylenecepham-4-carboxylate hydrochloride in 620 ml. of
X-420J -24inethanol was cooled in a dry ice-acetone bath and ozone was bubbled through the cold solution for about 20 minutes. The reaction mixture was purged of the remaining ozone by passing nitrogen through the solution and 10 g. of sodium bisulfite were added.
The reaction mixture was stirred for one hour at ice-bath temperature at which time the mixture gave a negative potassium iodide starch test.
The mixture was evaporated in vacuo to yield the reaction product as an amorphous yellow residue. The residue was crystallized in acetone to yield 5*4 g. of p-nitrobenzyl 7-amino-5-hydroxy-5-cephem-4-carboxylate hydrochloride as a crystalline acetone solvate.
I.R. (Nujol Mull):
Carbonyl absorption bands at 5*60 (β-lactam) and 6.04 (ester carbonyl hydrogen bonded to 5 hydroxy) microns.
N.M.R. (DMSO d<sub>6</sub>) signals at 7,92 (s, JH, 1/2 mole acetone), 6.22 (2d, 2h, C<sub>2</sub>-H<sub>2</sub>), 07. ל (d, 20 1H, C<sub>e</sub>H), 4.8-4.ל (m, 5H, ester CH<sub>2</sub> and C<sub>7</sub>H),
2.4-1.6 (m, 4h, aromatic H) tau.
Example 5 p-Nitrobenzyl 7 - [2-(2-thienyl)acetamido] -5-hydroxy-5-cephem-
4- carboxylate.
To a solution of 1.55 g. of p-nitrobenzyl 7-amino-
5- hydroxy-5-cephem-4־carboxylate hydrochloride in 5.0 ml. of acetone containing 564 mg. (0.5 ml., 5.6 mmole) of triethylamine was added 962 mg. of urea. With stirring at room temperature, a solution of 750 mg. (4.4 mmole) of 2-thiophene
X-4205 ־25־ acetyl chloride in 20 ml. of acetone was added dropwise to the mixture. After 2.5 hours the reaction mixture was filtered and evaporated. The residue was dissolved in ethyl acetate and the solution was washed successively with water, a 5 percent solution of sodium bicarbonate, 5 percent hydrochloric acid, and a saturated solution of sodium chloride. The washed solution was dried and then was concentrated by evaporation in vacuo to yield 1.2 g. of the reaction product as a crystalline residue. The product was recrystallized from ethyl 10 acetate to yield pure.p-nitrobenzyl 7-[2-(2-thienyl)acetamido]3-hydroxy-3-cephem-4-carboxylate having the following spectral properties.
I.R. (Nujol Mull):
Absorption peaks at 3.0 (amide NH), 5-68 (β-lactam carbonyl), and 6.1 (amide, and ester hydrogen bonded to 3 OH) microns.
N.M.R. (CDCI3/DMSO d<sub>e</sub>):signals at 6.5k (2d, 2H, C2H2), 6.16 (s, 2H, side-chain CH2), 4.90 (d, 1H, C<sub>e</sub>H), 4.60 (d, 2H, ester CH<sub>2</sub>),
4.43 (q, 1H, C<sub>7</sub>H), 3.1-1.6 (m, TH, aromatic h), and I.30 (d, 1H, amide NH) tau.
B. Preparation of Sulfonate Esters
Example 4 p-Nitrobenzyl 7-[2-(2-thienyl)acetamido]-3-methylsulfonyloxy3-cephem-4-carboxylate.
To a solution of 4.75 g. (10 mmole) of p-nitrobenzyl T-[2-(2-thienyl)acetamido] -3-hydroxy-3-cephem-4-carboxylate in 50 ml. of dry dimethylacetamide were added 2 ml. of propylene oxide. To the solution was added with stirring one equivalent 30
X-42O3 of methanesulfonyl chloride and stirring was continued for J hours. The reaction mixture was then taken up in ethyl, acetate and the solution was washed with a saturated solution of sodium chloride. The washed organic phase was evaporated in vacuo to dryness to obtain the reaction product mixture as a residue. The reaction product was purified by preparative thin layer chromatography on silica gel using for elution 65 percent ethyl acetate/hexane.
The purified product gave the following percent elemental composition on microanalysis.
Calculated for C21H19N3O9S3
Theory: C, U5.56; H, 3«U6; N, 7.595.5, 17.38 Found: C, A5.7M H, 3.565 N, 7.30; S, 17-06 The nuclear magnetic resonance spectrum and the infrared absorption spectrum were in agreement with the structure of the product formed.
N.M.R. (DMSO d<sub>e</sub>) delta values: 3.U7 (s, 3H, methyl); 3.80 (broad s, 2H, side chain CHg);
3.91 (q, 2H, C<sub>2</sub>H2); 5.29 (d, 1H, C<sub>e</sub>H);
5-U6 (broad s, 2H, ester CH2)5 5 . 8U (q, 1H,
C<sub>7</sub>H); 6.86-7Λ4 (m, 3H, thiophene); and 7.9θ (q, Uh, phenyl).
I.R. (mull) 1785, 1350, and 1158 cm<sup>1</sup>־
U.V. (Ethanol) !max 26U mg.
The above product (2 g.) was dissolved in a solvent mixtyre of 15 ml. of methanol and 20 ml. of tetrahydrofuran and 3 g. of prereduced 5 percent palladium on carbon catalyst were added. (The catalyst had been prereduced in 15 ml. of methanol for 1 hour prior to use.) The mixture was hydrogenated
X-U203 ז<sup>2</sup>־־for 1.5 hours during which time the theoretical hydrogen uptake had occurred.
The catalyst was filtered and the filtrate was evaporated to dryness on a rotary evaporator in vacuo. The residue was dissolved in 20 ml. of ethyl acetate and 20 ml. of cold water were added. The pH of the solution was adjusted to pH 7 with a solution of sodium bicarbonate and the organic layer was separated. Ethyl acetate was layered over the aqueous phase and the pH adjusted to 2,0 with׳ IN hydrochloric j_q acid. The organic layer was separated and combined with an ethyl acetate extract of the acidified aqueous layer. The combined extract and organic layer were dried over magnesium sulfate and evaporate to dryness to yield the de-esterified product, 7-[2-(2-thienyl)acetamid03-5-methylsulfonyloxy-5-
c.ephem-L-carboxylic acid.
N.M.R. (acetone de) delta values: 3.55 (s, 5H, methyl); 3.50-U.OO (m, Ml, two CH<sub>2</sub>); 5.10 (d, 1H, C<sub>Q</sub>H)5 5.88 (d, 1H, C<sub>7</sub>H); 6.80-7^0 (m, JH, thiophene).
I.R. (KBr) 1795, 1175 cm<sup>1</sup>־
U.V. (Ethanol)λ max 265 ωμ. (shoulder)
Electrometric titration (80 percent aqueous methyl cellosolve) pK<sub>a</sub> 5-9.
Example 5
7-[2-(2-Thienyl)acetamido] -5-ethylsulfonyloxy-5-cephem-Ucarboxylic acid.
By following the procedure described by Example U, U.7 g. (lOmmole) of p-nitrobenzyl 7-(2-(2-thienyl )acetamido]-
5-hydroxy-5-cephem-<sup>1</sup>+-carboxylate was reacted for about 5 hours 50
X-U2O5 in JO ml. of dimethylacetamide containing about 2 ml. of propylene oxide with a stoichiometric amount of ethanesulfonyl chloride. The reaction mixture was dissolved in ethyl acetate and the solution washed with a saturated solution of sodium chloride. The organic phase was dried and evaporated to dryness to provide the reaction product. The product was purified by preparative thin layer chromato graphy on silica gel by employing 65 percent ethyl acetate/hexane for development.
The purified product, p-nitrobenzyl 7-[2-(2-thienyl)acetamido] 10 3-ethylsulfonyloxy-3-cephem-4-carboxylate, gave the following percent elemental composition on microanalysis for the formula C22H21N3O9S3:
Theory: C, 46.55; H, 3.75; N, 7.40; S, 16.95 Found: 0, 46.32; H, 3.48; N, 7-5; S, 16.67
I.R. (chloroform) 1800, 135θ, 1163 cm“<sup>1</sup>
U.V. (ethanol) λ max 265 tup.
N.M.R. (CDCI3) delta values: 1.47 (τ, 3H, methyl);
3.40 (q, 2H, CH2); 3.73 (9, 2H, C<sub>2</sub>-CH<sub>2</sub>);
3.88 (s, 2H side chain CH<sub>2</sub>); 5.13 (d, IH,
C<sub>e</sub>H); 5.20 (s, 2H, ester CH<sub>2</sub>); 5.91 (9, IH,
C<sub>7</sub>H); 6.85 (d, 2H, NH); 7.00-7.44 (m, 3H, thiophene); 7-96 (9, 4h, phenyl).
The above product was hydrogenated to effect removal of the p-nitrobenzyl ester group by following the hydrogenation method described in Example 4, to provide 7-(2(2-thienyl)acetamido] -5־ethylsulfonyloxy-3-cephem-4-carboxylic acid.
X-42O3
N.M.R. (CDC13+acet'0ne d<sub>e</sub>) delta values: 1.U5 (τ, 5H, methyl); 3.U1 (q/2h, CH<sub>a</sub>); 3.69 (q, 2H, ring CH2); 3.8U (s, 2H, side chain CH<sub>a</sub>); 5.12 (d, IH, C<sub>e</sub>-H); 5.85 (q, IH, C<sub>7</sub>-H)s 6.88-7.32 (m, 3H, thiophene).
I.R. (mull) 1787, 1350 and 1170 cm“<sup>1</sup>
Electrometric titration in 80 percent aqueous methyl cellosolve pK<sub>a</sub> h. 15 .
Example 6
7- [2- (2-Thienyl)acetamido'} -3־n-butylsulfonyloxy-3־cephem-Ucarboxylic acid.
By following the esterification procedure of Example U, U.7 g. of p-nitrobenzyl 7-[2-(2-thienyl)acetamido] 3-hydroxy-3-cephem-U-carboxylate was reacted with the stoichiometric amount of n-butylsulfonyl chloride in dimethylacetamide containing propylene oxide to provide 2.1 g. of the 5-n-butylsulfonyloxy derivative.
Percent elemental composition for C<sub>24</sub>H25<sup>N</sup>309S3<sup>:</sup>
Theory: C, U8.39, H, ^.2}; N, 7-05 20 <sub>x</sub>
Found: C, U7.9^i Η, <sup>1</sup>+.275 N, 6.31
N.M.R. (DMSO d<sub>e</sub>) delta values: 0.87 (t, 3H, methyl);
, 1.10-1.90 (m, Uh, two CH<sub>h</sub>); 2.U5-2.87 (m, 2H, CH2); 3.71 (q, 2h, ring CH<sub>2</sub>); 3.79 (s, 2H, side chain CH<sub>2</sub>); 5-2B (d, IH, C<sub>e</sub>H); 5Λ2 (broad s, 2H, ester CH<sub>2</sub>); 5.82 (q, IH, C<sub>7</sub>h); 6.50-6.97 (m, 3Η, thiophene); 8.07 (q, Uh, phenyl).
I.R. (CHCI3) 1801, 1355, 1170 cm<sup>1</sup>־
3°
X-U203 ־50־
The p-nitrobenzyl ester group is removed from the above n-butylsulfonyl derivative by following the hydrogenolysis method described by Example 4 to provide 7-[2-(2-thineyl)acetamido] -J-n-butylsulfonyloxy-J-cephem-U-carboxylic acid,
N.M.R. (CDCI3) delta values: 0.9θ (t, 5H, methyl); 1.10-2.00 (m, 4h, two CH<sub>2</sub>); 2.655.00־ (m, 2H, CHg); 5.60-4.10 (m, 4h, C<sub>2</sub> and side chain CH<sub>2</sub>); 5.09 (d, 1H, C<sub>6</sub>H); 1 ,9) <sup>8</sup>?.לh, C<sub>7</sub>H); 6.857.58 (m, 5H, thiophene).
I.R. (CHCI3) 17θ7, 1560 cm<sup>1</sup>
Electrometric titration in 80 percent aqueous methyl cellosolve pK<sub>a</sub> 4.75.
Example 7
7-[2-(2-Thienyl)acetamido] -5-(p-toluenesulfonyloxy)-5-cephem4-carboxylic acid.
To a solution of 9-5 g. (<sup>2</sup>θ mmole) of p-nitrobenzyl 7-[2-(2-thienyl)acetamido]-5-hydroxy-5-cephem-4-carboxylate in 50 ml. of DMAC and 50 ml. of propylene oxide maintained at icebath temperature were added 4.2 g. (22 mmole, 1.1 equivalents) <sup>2</sup>θ . .
of p-toluenesulfonyl chloride. The reaction mixture was stirred at ice-bath temperature for about 15 hours and then for about 5 hours at room temperature. Thereafter, the reaction mixture was evaporated to remove excess propylene oxide and the concentrate <sup>,</sup>was dissolved in ethyl acetate. The solution was washed with a saturated sodium chloride solution and dried. Evaporation of the dried solution under reduced pressure afford the crude tosylate ester as a dry residue. The residue was dissolved in ethyl acetate and chromatographed over waterdeactivated silica gel (Woelm silica gel, 10. percent water
X-4205 ־<sup>51</sup>־ deactivated) packed in a glass column. The column was eluted with 45 percent by volume of hexane in ethyl acetate. Four fractions of approximately 100 ml. volume were collected. Fractions 2 and J were combined and evaporated under reduced pressure to yield 4.75 g« of p-nitrobenzyl 7-[2-(2-thienyl)acetamido)-5-(p-toluenesulfonyloxy)-3-cephem-4-carboxylate mixed with the corresponding 2-cephem isomer.
To a solution of 1.26 g. of the isomeric mixture in ml. of methylene chloride maintained at ice-bath tempera.10 ture was added a solution of 0.4 g. of m-chloroperbenzoic acid in 20 ml. of methylene chloride. The mixture was stirred for 40 minutes and was evaporated to dryness. The residue was triturated with iso-propanol, filtered, washed with ether and dried to yield 1.1 g. of product, p-nitrobenzyl 7-(2-(2thienyl)acetamido)-5-(p-toluenesulfonyloxy)-3-cephem-4-carboxylate sulfoxide. Percent elemental composition of the sulfoxide product, calculated for C27H23N30!<sub>o</sub>S3, was as follows: Theory: C, 50.2?; Η, 3.59> N, 6.51 Found: C, 49.98; Η, 3.5Ο; N, 6.53
The A<sup>3</sup>-cephem sulfoxide was reduced to the A<sup>3</sup>-cephem sulfide as follows:
To a solution of 1.0 g. of the sulfoxide in 25 ml.
of acetonitrile containing 5 ml. of DMF maintained at ice-bath temperature were added 0.157 g. of phosphorus tribromide with stirring. The reaction mixture was stirred for 1 hour in the cold. Ethylacetate and a saturated aqueous sodium chloride solution were added to the mixture. The product was extracted with the ethyl acetat'e and the organic layer was washed 3 times with a saturated sodium chloride solution. The organic 30 phase was dried and evaporated to yield 1.1 g. of the product,
X-4203 -52p-nitrobenzyl 7-[2-(2-thienyl)acetamido<sup>-</sup>] -5-(p-toluenesulfonyloxy)-5-cephem-k-carboxylate.
The above product was hydrogenated over prereduced i 5 percent palladium on carbon catalyst in methanol-THF by the procedure described in Example 4 to provide the free carboxylic acid product, 7-[2-(2-thienyl)acetamido]-5-(ptoluenesulfonyloxy)-5-cephem-4-carboxylic acid.
N.M.R. (CDCI3) delta values: 2.47 (8, 5H, methyl); 5*40-4.10 (m, 4h, C2 and side chain CH2);
5.05 (d, 2H, C<sub>e</sub>H); 5.80 (q, IH, C<sub>7</sub>-h); 6.85-7-58 (m, 5H, thiophene); 7.61 (q, 4h, phenyl).
I.R. (CHCI3) 1790, 1580, 1170 cm<sup></sup>
Electrometric titration (80 percent aqueous methyl cellosolve) pK<sub>a</sub> 4.4.
U*V. (ethanol) λ max 265 mq. (shoulder).
Example 8 7-[2-(2-Thienyl)acetamidoJ-5-(4-fluorobenzenesulfonyloxy)-5cephem-4-carboxylic acid.
By following the sulfonation and de-esterification procedures described in Example 4 p-nitrobenzyl 7-(2-(2thienyl)acetamido]-5-hydroxy-5-cephem-4-carboxylate was reacted with 4-fluorobenzenesulfonyl chloride in DMAC in the presence of propylene oxide and the recovered sulfonation product, p-nitrobenzyl 7- [2-(2-thienyl)acetamido] -5-(4-fluorobenzenesulfonyloxy)-5-cephem-4-carboxylate was hydrogenated in methanol-THF over pre-reduced 5 percent palladium on carbon catalyst to provide the product, 72)-2) ־-thienyl)acetamido]-5(4-fluorobenzenesulfonyloxy)-5-cephem-4-carboxylic acid.
X-42O5 -35Percent elemental ׳analysis obtained on microanalysis for CχθΗ25Ν20γ83Κi
Theory: C, 45*78; H, 5.05; N, 5-62; F,5-81 Found: C, 46,04; H, 5-51; N, 5.55; F, 5.89 N.M.R. (CDC13) delta values: 5.48-4.10 (broad m, 4h, C<sub>2</sub> and side chain CH<sub>2</sub>); 5.05 (d, 1H, C<sub>e</sub>-H); 5.77 (q, 1H, C<sub>7</sub>-H); 6.80-7.48 and 7.778.16־ (broad m, TH, thiophene and phenyl H).
I.R. (CHC1<sub>3</sub>) 1T92, 1585, and 1160 cm<sup>1</sup>־
Electrometric titration (80 percent aqueous methyl cellosolve) pK<sub>a</sub> 4.25Example 9
T- (D-phenylglycylamido ) - 5-methylsulfonyloxy-5-cephem-4carboxylic acid.
To a solution of 11.1 g. of p-nitrobenzyl T-amino-5hydroxy-5-cephem-4-carboxylate hydrochloride in 500 ml. of tetrahydrofuran were added 11.ל g. of sodium bisulfite. The mixture was stirred at room temperature for 1 hour and 6.4 g. of N-(t-butyloxycarbonyl)phenyglycine and 6.25 g. of N-ethoxy20 carbonyl-2-ethoxy-l,2-dihydroquinoline (EEDQ) were then added.
The reaction mixture was stirred at room temperature for 7 hours after which the mixture was evaporated to remove tetrahydrofuran. The concentrate was dissolved in ethyl acetate and the solution was washed consecutively with a solution of sodium bicarbonate, dilute hydrochloric acid and a saturated sodium chloride solution and was dried. The dried solution was evaporated to dryness to yield 11.14 g. of p-nitrobenzyl T-(N-t-butyloxycarbonyl-D-phenylglycylamido )-5-hydroxy-5cephem-4-carboxylate.
X-4205 J<sup>1</sup>»
To a solution of 11.14 g. of the above product in 50 ml. of DMAC containing 25 ml. of propylene oxide were added at room temperature 1.4ץ ml. of methanesulfonyl chloride.
After the mixture was stirred for about 3 hours, an additional . 1.4ץ ml. of methanesulfonyl chloride were added and the mixture was stirred for an additional 15 hours. The reaction mixture was diluted with ethyl acetate and the solution extracted 4 time with a saturated solution of sodium chloride. The washed organic phase was dried and evaporated to dryness to yield crude reaction product, p-nitrobenzyl 7-(N-t-butyloxycarbonylD-phenylglycylamido)-3-methylsulfonyloxy-3-cephem-4-carboxylate. The product was purified by dissolution in methylene chloride and precipitation from solution on dilution with hexane. The purified product, 8.09 g. <sup>was</sup> filtered and dried.
The p-nitrobenzyl ester group was removed by hydrogenation of the product over pre-reduced 5 percent palladium on carbon by the method described in Example 4, to yield 4.21 g. of the free acid.
The free acid obtained, 1.545 g. was dissolved in
3 ml. of dry acetonitrile and 1.7 g. of p-toluenesulfonic acid were added. The reaction mixture was stirred overnight at room temperature. Water was added to the mixture and the pH adjusted to 5.0 with a solution of sodium bicarbonate. The mixture was then evaporated to remove acetonitrile and the aqueous residue was filtered. The pH of the filtrate was adjusted to pH 4,0 and was then freeze dried. The freeze dried mixture was triturated with acetone and filtered. The solid was dissolved in. 15 ml. of water and about 5 ml. of acetone were added to the solution at ice-bath temperature. The product,
7- (D-phenylglycylamido )-3-methylsulfonyloxy)-3-cephem-4
X-4205 -55carboxylic acid, crystallized from the cold solution and was filtered, washed with cold water and with acetone and was dried to provide 143 mg.
Percent elemental composition for C!<sub>e</sub>H<sub>17</sub>N3O<sub>7</sub>S2:
Theory: C, 44.92; H, 4.01; N, 9.θ5 Found: C, 44.15; H, 4.24; n, 9.26 Electrometric titration in 80 percent aqueous methyl cellosolve pK<sub>a</sub> 5.6 and 6.75
I.R. (mull) 1780, 1560, and 1178 cm<sup>1</sup>־.
U.V. (pH 6 buffer) Amax 261 mp. (€ = 8400)
N.M.R. (DMSO d<sub>e</sub>) delta values: 5.28 (s, 3H, methyl); 5-55 ׳׳ (q, 2H, C2-CH2); 4.92-5.1 (m, 2H, C<sub>6</sub>H and CH of side chain); 5*68 (q, 1H, C<sub>7</sub>-H); 7.48 (m, 5H, phenyl).
Contents9
21 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21
353 members in 42 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 43920774 | United States of America | A | |
| 43920774 | United States of America | A | |
| 439207 | – | – | – |
| US19740439207 | – | – | – |
Members353
| Document | Office | Kind | |
|---|---|---|---|
| US945511A | United States of America | A | |
| US1419155A | United States of America | A | |
| US1855456A | United States of America | A | |
| US1891929A | United States of America | A | |
| US2359048A | United States of America | A | |
| US2373547A | United States of America | A | |
| IL44360A0 | Israel | A0 | |
| BE813170A | Belgium | A | |
| MW1174A1 | Malawi | A1 | |
| ATA312274A | Austria | A | |
| IE39068L | Ireland | L | |
| DE2417987A1 | Germany | A1 | |
| FI99374A | Finland | A | |
| FI99374A7 | Finland | A7 | |
| NO792632L | Norway | L | |
| SE7403306L | Sweden | L | |
| NL7403127A | Netherlands (Kingdom of the) | A | |
| JPS50108288A | Japan | A | |
| NO741092L | Norway | L | |
| AU6640474A | Australia | A | |
| GT197432531A | Guatemala | A | |
| DK119974A | Denmark | A | |
| ZA741424B | South Africa | B | |
| FR2269926A1 | France | A1 | |
| DD117466A5 | German Democratic Republic (until 1990) | A5 | |
| BR7404086A | Brazil | A | |
| AT329182B | Austria | B | |
| ES427236A1 | Spain | A1 | |
| IN139919B | India | B | |
| AR207327A1 | Argentina | A1 | |
| US3985737A | United States of America | A | |
| GB1457668A | United Kingdom | A | |
| EG11160A | Egypt | A | |
| PL90985B1 | Poland | B1 | |
| ZM5574A1 | Zambia | A1 | |
| IL44360AThis record | Israel | A | |
| HU170811B | Hungary | B | |
| SU576946A3 | Soviet Union (until 1991) | A3 | |
| CA1019322A | Canada | A | |
| PH11197A | Philippines | A | |
| CH596224A5 | Switzerland | A5 | |
| FR2269926B1 | France | B1 | |
| RO63020A | Romania | A | |
| IE39068B1 | Ireland | B1 | |
| CS185638B2 | Czechoslovakia (until 1993) | B2 | |
| BG25998A3 | Bulgaria | A3 | |
| OA04642A | African Intellectual Property Organization (OAPI) | A | |
| SE414769B | Sweden | B | |
| YU63274A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| FI60213B | Finland | B | |
| YU35891B | Yugoslavia, later Serbia and Montenegro (until 2006) | B | |
| FI60213C | Finland | C | |
| BE895048A | Belgium | A | |
| JPS5878711U | Japan | U | |
| US4469954A | United States of America | A | |
| CA1195380A | Canada | A | |
| JPS6123198B2 | Japan | B2 | |
| CH659920A5 | Switzerland | A5 | |
| WO0231683A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO0231805A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU1187902A | Australia | A | |
| AU1345602A | Australia | A | |
| US2002113820A1 | United States of America | A1 | |
| US2007005969A1 | United States of America | A1 | |
| US7168051B2 | United States of America | B2 | |
| KR20070017003A | Republic of Korea | A | |
| KR20070017004A | Republic of Korea | A | |
| KR20070017005A | Republic of Korea | A | |
| KR20070017006A | Republic of Korea | A | |
| KR20070017007A | Republic of Korea | A | |
| KR20070017008A | Republic of Korea | A | |
| KR20070017009A | Republic of Korea | A | |
| KR20070017010A | Republic of Korea | A | |
| KR20070017011A | Republic of Korea | A | |
| KR20070017012A | Republic of Korea | A | |
| KR20070017013A | Republic of Korea | A | |
| KR20070017014A | Republic of Korea | A | |
| KR20070017015A | Republic of Korea | A | |
| US2007030263A1 | United States of America | A1 | |
| US2007030289A1 | United States of America | A1 | |
| US2007030389A1 | United States of America | A1 | |
| US2007030390A1 | United States of America | A1 | |
| US2007030393A1 | United States of America | A1 | |
| US2007030394A1 | United States of America | A1 | |
| US2007030395A1 | United States of America | A1 | |
| CA2615762A1 | Canada | A1 | |
| CA2615764A1 | Canada | A1 | |
| CA2615877A1 | Canada | A1 | |
| CA2615878A1 | Canada | A1 | |
| CA2615879A1 | Canada | A1 | |
| CA2615880A1 | Canada | A1 | |
| CA2615881A1 | Canada | A1 | |
| CA2616089A1 | Canada | A1 | |
| CA2616095A1 | Canada | A1 | |
| CA2616096A1 | Canada | A1 | |
| CA2616243A1 | Canada | A1 | |
| CA2616255A1 | Canada | A1 | |
| CA2616257A1 | Canada | A1 | |
| US2007035469A1 | United States of America | A1 | |
| US2007035470A1 | United States of America | A1 |
Numbers
- Publication, DOCDB
- 44360
- Publication, EPODOC
- IL44360
- Application
- 44360
- Application, DOCDB
- 4436074
- Application, EPODOC
- IL19740044360
Titles
- English
- 7-ACYLAMIDO-3-HYDROXY-3-CEPHEM-4-CARBOXYLIC ACID 3-SULFONATES
Classification
- CPC, 2
- C07D501/20
- A61P31/04
- IPC, 14
- C07D501 59
- A61K31 545
- A61K31 546
- A61P31 04
- C07C
- C07D
- C07D499 00
- C07D501 00
- C07D501 04
- C07D501 16
- C07D501 20
- C07D501 24
- C07D501 28
- C07D501 60
